RecruitingNCT06371976

Evaluation of the HPA Axis in Patients With Vasoplegic Syndrome After Cardiac Surgery

Evaluation of the Hypothalamic-pituitary-adrenal Axis in Patients With Vasoplegic Syndrome After Cardiac Surgery


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

200 participants

Start Date

Mar 5, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Vasoplegic syndrome after cardiac surgery is common and is associated with increased morbidity and mortality. It is characterized by early and prolonged arterial hypotension, with preserved cardiac output and low systemic vascular resistance. Vasoplegic syndrome therefore shares pathophysiological features with septic shock. There are no data in the literature on the function of the hypothalamic-pituitary-adrenal (HPA) axis during vasoplegic syndrome after cardiac surgery. In situations of acute stress and systemic inflammation, relative adrenal insufficiency has been reported in the most severe patients, particularly those in septic shock. The term ""CIRCI"" (Critical Illness-Related Corticosteroid Insufficiency) is currently defined as an increase in total plasma cortisol of less than 9 µg/dl after stimulation with 250 µg tetracosactide (synthetic ACTH), or a basal total plasma cortisol level of less than 10 µg/dl. However, recent studies have called into question the usefulness of the cosyntropin stimulation test for exploring the HPA axis in intensive care patients. Tandem mass spectrometry (LC-MS/MS) assays can be used to measure steroid metabolites (steroidome), enabling more precise exploration of the corticotropic axis. The aim of this study is to evaluate, on an exploratory basis, the impact of the presence of a post-cardiac surgery vasoplegic syndrome on adrenal function by steroidome mapping (LC-MS/MS).


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Age ≥ 18 years
  • Scheduled cardiac surgery with extracorporeal circulation
  • Patient or trusted person or legal representative informed and having expressed non-opposition to participation in the study.

Exclusion Criteria5

  • Previous treatment within the last 3 months with glucocorticoids, azoles (Fluconazole, Voriconazole), phenytoin, rifampin, glitazones (Rosiglitazone or Pioglitazone), imipraminics (Clomipramine, Imipramine, Amitriptyline), barbiturates (Primidone, Phenobarbital, Thiopenthal) or phenothiazines (Chlorpromazine, Cyamemazine).
  • Adrenal or intracranial pathology affecting the hypothalamic-pituitary axis.
  • Cardiac transplants.
  • Post-operative mechanical extracorporeal assistance.
  • Patient deprived of liberty by judicial or administrative decision.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood sampling

Blood samples of 5 mL are taken at 4 stages of the study. Samples are taken from an arterial catheter inserted as part of the treatment, for a total volume of 20 mL maximum for the study.

OTHERVital status

Patients will be followed until their discharge from intensive care, or at most until D28, and their vital status will be collected at the end of their participation in the study.


Locations(1)

Pitié-Salpêtrière

Paris, Île-de-France Region, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06371976